Oncology
5 drugs are in development for Esophageal Cancer.
- Companies
- 5
- Clinical trials
- 59
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Esophageal Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ngm120 | NGM BIOPHARMACEUTICALS INC (NGM) |
Phase 1(2)
| Drug | Company |
|---|---|
| AB308 | Arcus Biosciences, Inc. (RCUS) |
| STRO-004 | SUTRO BIOPHARMA, INC. (STRO) |
Phase 1/Phase 2(2)
About this indication
Esophageal Cancer context
Oncology·MeSH: Esophageal Neoplasms (D004938)
Narrower concept of MeSH descriptor Esophageal Neoplasms
Prevalence
13.9 / 100K
Incidence
8.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Esophageal Cancer?
BioSniper tracks 5 drugs in development for Esophageal Cancer across 5 companies.
How many clinical trials target Esophageal Cancer?
There are 59 clinical trials targeting Esophageal Cancer tracked by BioSniper.
What is the prevalence of Esophageal Cancer?
The estimated prevalence of Esophageal Cancer is approximately 13.9 per 100,000 population.